Invirsa, a Columbus-based pharmaceutical company, today announced execution of a license agreement with the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital as Invirsa seeks to broaden its treatment platform to address respiratory diseases.
The announcement coincides with Invirsa’s securing a $16.9 million contract from the government agency involved in the development of medical countermeasures. The contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, will help move Invirsa’s investigational product INV-102 to clinical trials and request FDA approval. The contract includes options for an additional $12.6 million upon completion of scientific milestones.
Click here to read the complete story.
Written by CINCYTECH.
Originally published Dec. 18, 2020.